Summary Covalent linkage of the A chain of ricin to the LICR-LOND-Fib75 monoclonal antibody produced an immunotoxin, Fib75-SS-ricin A, which demonstrated immunospecific toxicity to human bladder carcinoma cells in tissue culture (Forrester et al., 1984 
The plant toxin ricin comprises two polypeptide subunits, A and B, joined by a disulphide bond. It binds to galactosecontaining receptors on the surface of mammalian cells via its B chain (Olsnes & Pihl, 1973) . The toxin subsequently enters the cells by receptor-mediated endocytosis where its toxicity is expressed by the inactivation of protein synthesis following the translocation of the A chain to the cytoplasm. Hybrid molecules, comprising monoclonal antibodies chemically coupled to the A chain of plant toxins (immunotoxins) (Lord et al., 1985) have shown promise in the treatment of experimental animal tumours and are presently proving to be increasingly useful alternatives to conventional diffusible drugs in the treatment of neoplastic disease (Coombes et al., 1986) . Immunotoxins act by terminating protein synthesis in the target cells. Following binding by antibody recognition of plasma membrane antigens, conjugates enter cells by receptor-mediated endocytosis (Carriere et al., 1985) . After gaining access to the cytoplasm, the toxin A chain of the conjugate catalytically cleaves adenine residue 4324 in the 28S ribosomal RNA of the 60s ribosomal subunit, irreversibly halting cellular protein synthesis (Endo & Tsurugi, 1987) . Thus the antibody molecule acts as a surrogate B chain to bring about immunospecific cell death. The LICR-LOND-Fib75 (Fib75) monoclonal antibody recognises an HLA class I-related plasma membrane antigen found in all differentiated human cells except those of the lymphoid system (Buckman et al., 1982) . Fib75 was covalently linked to the A chain of ricin to produce an immunotoxin that displayed an immunospecific and moderate toxicity to target cells in culture, but whicti was two orders of magnitude less toxic than the parent toxin (Forrester et al., 1984) . A-chain immunotoxins which lack the galactose-binding B chain polypeptides are often less cytotoxic than their holotoxin counterparts (Martinez et al., 1982) . Hence different methods have been employed to potentiate the cytotoxicity of A chain conjugates while maintaining their immunospecificity. Agents which have been investigated for their ability to potentiate immunotoxin activity include the lysosomotropic amines, ammonium chloride and chloroquine (Ramakrishnan et al., 1989) , carboxylic ionophores such as monensin (Griffin et al., 1987 ) and the addition of free or antibody-conjugated toxin B chains following immunlocalisation of the A chain conjugate (Vitetta et al., 1983; McIntosh et al., 1983) . The expressed as percentages of the levels of synthesis in appropriate control cultures. In experiments where the timecourse of protein synthesis inhibition was assayed, cells were exposed to either ricin, Fib75-SS-ricin A or conjugate plus ricin B chain for 1 h. For the earliest (1 h) timepoints, 5 ItCi 3H-leucine of a higher specific activity than that used for the standard assays (120-190 Ci mMol ') was added to the cultures exposed to the treatments in leucine-free medium. For subsequent timepoints, the cells were washed free of toxin, conjugate and conjugate plus B chain/lactose and incubated in serum-free medium. Cultures were then pulsed for 20 min before harvesting as described above. For ultrastructural studies 4 x I05 cells were plated out (in triplicate) overnight in 30 mm Petri dishes (Sterilin) to allow the cells to adhere before processing. A mouse bladder carcinoma cell line MB49 was used as a specificity control.
Antibodies
Gold conjugates, anti-rabbit (GIO) and anti-mouse (G5) IgGs were obtained from Janssen (Belgium Prepartion of ricin B chain Essentially this method involves cleavage of the holotoxin disulphide bond while the toxin is immobilised on an agarose matrix via the binding site of the B chain. One hundred to 150 mg of the toxin was loaded onto an acid-treated Sepharose 4B column (bed volume 25 ml) equilibrated with 0.1 M phosphate buffer, pH 8.0, containing 1 mM EDTA. The column was then washed with four bed volumes of running buffer to elute both non and partially bound material. Running buffer (15 ml) containing 5% 2-mercaptoenthanol was loaded and the flow of buffer was then stopped and the column allowed to stand for 2h to allow cleavage of the disulphide linkages. The toxin A chain was eluted leaving the B chain and uncleaved toxin still bound to the column. The B chain was eluted from the column with 500 mM galactose, 100 mM Na2PO4, 5% 2-mercaptoethanol, 150 mM NaCl pH 8.8. The eluted protein peak was dialysed against the running buffer for ion exchange chromatography. A column of LKB CM-Trisacryl (40 ml bed volume) was equilibrated with 10 mM phosphate buffer at pH 6.0 containing 100 mM galactose and 0.5% 2-mercaptoethanol and set to run at 14 ml h-' collecting 4 ml fractions. The dialysed B chain was applied to the column and the breakthrough peak containing the unbound fraction was collected.
The B chain was dialysed against the running buffer for chromatofocussing. A column of PBE94 (bed volume 30 ml) was equilibrated with 0.025 M histidine/HCl buffer at pH 6.2 containing 20 mM galactose and approximately 50 mg of dialysed B chain was applied to the column. The column was washed with 2-3 column volumes and a pH gradient formed by eluting with 12 column volumes of 1/8 dilution of Polybuffer 74 at pH 4.0 containing 20 mM galactose. The diluent used was distilled water and 1.0 M HCI to adjust the pH of the polybuffer. Pure B chain was focussed at its PI of 4.8.
Ultrastructural immunocytochemistry
The target cells were incubated with 10-7 M Fib75-SS-ricin A at 4°C for 15 min in medium containing FCS. The cells were then washed three times in cold phosphate buffered saline (PBS). In experiments in which ricin B chain was used following immunotoxin binding, 10-7M ricin B chain was added to the Fib75-SS-ricin A-labelled cells in the presence of 100 mM lactose for an additional 15 min at 4°C. At the end of the incubation the cells were washed three times in PBS. The antibody component of the conjugate was labelled by incubation with a 1/10 dilution of a goat anti-mouse IgG-G5 conjugate (Janssen) for 15 min at 4°C. The cells were then washed three times in PBS to remove the unbound label. The A chain of the toxin was labelled by a 15 min incubation with a polyclonal rabbit anti-ricin antibody (22 ;tg ml-') followed by a 1/10 dilution of GIO-labelled goat-anti-rabbit conjugate. To follow the fate of ricin B chain in the cells the B chain was bound to the cell surface at 4°C for 15 min at 10-M and the cells were washed as described above. The surface-bound ligand was then labelled with a rabbit antiricin polyclonal antibody (22lLgml-'). Labelling was completed with the addition of a goat anti-rabbit gold conjugate (GIO). Preparations for the identification of plasma membrane bound ligands were fixed in 1% glutaraldehyde: 0.08 M cacodylate buffer pH 7.2 for 1 h at room temperature and processed as described below. Other cells were re-incubated in serum-containing medium at 37°C for various times up to 20 h to allow the internalisation of the labelled complex and then washed and fixed as described above.
Processing of cells for electron microscopy After the first fixation, all cells were washed in cacodylate buffer and post fixed in 1% OS04 in the same buffer for a further hour. The monolayers were then washed with distilled water for 30 min and dehydrated in a graded series of alcohols. The cells were floated off the surface of the Petri dishes with propylene oxide. The cell pellet was centrifuged at 1,000 r.p.m. and embedded in Araldite (EMScope). Ultra thin sections were cut using a diamond knife, stained in lead citrate and examined in a Phillips EM-100 electron microscope at an accelerating voltage of 80 Kv.
Quantification
Ten randomly selected cells were photographed at a minimum magnification of 10,000 x. The 10 nm gold particles in subcellular compartments labelling ricin chains were counted and expressed as a percentage of the total particle number at a given time point. The total particle number per cell at each time point exceeded 300.
Binding and internalisation of native ligands Immunotoxin or B chain-treated immunotoxin was bound to the cell surface as described above and internalisation of ligands was allowed to continue for different time periods. The cells were washed in PBS and fixed in 2% paraformaldehyde/PBS for 30 min. The cells were then washed in PBS and permeabilised with 0.05% saponin/PBS (wt/v) for 45 min at room temperature after which the cells were washed extensively in PBS. Intracellular ricin A and B chains were detected by a 1 h incubation of the monolayer with rabbitanti-ricin IgG (22 iLg ml-') in PBS containing 0.05% saponin followed by extensive washes with PBS and a second antibody incubation with swine-anti-rabbit IgG-peroxidase conjugate (1/15 dilution in PBS/0.05% saponin). After three washes in PBS the cell monolayers were incubated for 30 min at room temperature in 2 ml PBS containing 1 mg diaminobenzidine (DAB) and 2 iLl H202 (15%). After several PBS washes the cell monolayer was fixed in OS04 and processed for electron microscopy as described above. Fib75 monoclonal antibody, either free or conjugated, was detected by a 1 h incubation with a rabbit-anti-mouse IgG peroxidase con-jugate at a 1:25 dilution in PBS/0.05% saponin. The cells were then processed as described previously. Preparations lacking the primary antibody served as negative controls for ricin A chain detection. For Fib75 controls, a rabbit-antigoat IgG-peroxidase conjugate was used. Additionally, a mouse bladder carcinoma cell line, MB49 was used as specificity control.
Results
Plasma membrane localisation ofgold-labelled ligands at 4°C The immunotoxin was found in a patchy distribution on the plasma membrane appearing as a mixutre of 5 and 1O nM gold particles (monoclonal antibody and ricin A chain respectively) (Figure la, b) . The Fib75-SS-ricin A with associated ricin B chain was found localised in coated pits as has been observed previously for ricin holotoxin (Van Deurs et al., 1986; McIntosh et al., 1990) as well as in discrete areas of the plasma membrane (Figure 2a ). Fib75 antibody was seen as fairly evenly distributed label on the plasma membrane but was absent from coated areas. In the presence of 100 mM lactose no binding of ricin B chain to the cell surface was seen (data not shown). B chain added to cell monolayers without Fib75-SS-ricin A and in the absence of 100 mM lactose bound to the plasma membrane and was seen as small clusters of GIO gold label. No plasma membrane labelling was observed when either the MB49 mouse tumour was treated in place of the EJ cells or when the primary antibodies were omitted from the labelling procedures.
Internalisation ofgold-labelled ligands After 5 min at 37°C the immunotoxin molecules were transferred to cytoplasmic endosomal compartments. The immunotoxin complex without B chain entered the cell exclusively in uncoated pits and vesicles (Figure lc) while immunotoxin bearing ricin B chain entered cells predominantly (83%) in coated pits and coated vesicles, in a manner previously described for ricin holotoxin (Figure 2a and b) . Components of Fib75-SS-ricin A were seen occasionally separated in early endocytic compartments suggesting a certain degree of lability of the conjugate.
In treatments using free B chain, the B chain was seen in the endosomes; some still remained on the plamsa membrane. Thirty to 60 min after internalisation of the immunotoxin complexes the most heavily labelled compartments were the endosomes and to a lesser extent the multivesicular endosomes; some label was also observed in secondary lysosomes (Figures 3a, b, c and 4a, b, c) . All of these compartments contained both G5 and GIO gold particles indicating no further dissociation of the conjugate. In addition to the continuous presence of label at the plasma membrane, cells treated with Fib75-SS-ricin A plus ricin B chain started to generate vesicles labelled with both 5 nm and 1O nm gold particles which appeared at the cell surface; these vesicles were absent in cells treated with either Fib75-SS-ricin A alone or ricin B chain alone (McIntosh et al., 1990) . In cells internalising the immunotoxin-gold complex the gold particles were found to be aggregated in some multivesicular endosomes indicating that degradation of the protein component of the complex was taking place (Figure 3d ). Aggregation of gold label in multivesicular endosomes at this timepoint was not seen in cells treated with immunotoxin plus ricin B chain and was not observed as a consequence of ricin toxicity in a previous study (Figure 4c ). Twenty-four hours after internalisation of the complex the Fib75-SS-ricin A-treated cells contained the 5 and 1O nm gold complexes mostly in secondary lysosomes ( Figure 5 ). Cells treated with the immunotoxin plus ricin B chain showed signs of cellular damage and contained far less lysosome-associated gold label ( Figure 6b) ; most of the label was found extracellularly, mainly associated with plasma membrane vesicles ( Figure  6a ). In control samples both Fib75 antibody and ricin B Figure 1 Fib75-SS-ricin A immunolocalisation at 4°C on EJ cells. G5 gold label represents Fib75 and GIO, ricin epitopes. a, label is localised in a well-defined area. Bar = 0.1 s; b, Coated pit is unlabelled. Bar = 0.1 t; c, Fib75-SS-ricin A, 5 min after incubation at 37°C. Note the presence of label at the cell surface and in uncoated pit/vesicles. There is an apparent separation of G5 and GIO particles in certain vesicles. There is an apparent separation of G5 and G10 particles in certain vesicles. Bar = 0.1 t. chain were found in the lysosomes 24 h after internalisation and no cell surface labelling remained.
Quantification ofgold label Morphometric analysis (based on calculations of 3,000 particles per sample) of the amount of GIO label (ricin A chain) found in cellular compartments showed significant differences between the internal distribution of Fib75-ricin A chain complexes with and without ricin B chain. It should be noted that ricin B chain may also have been labelled with the GIO since the polyclonal antibody used was raised against ricin holotoxin. The immunotoxin and B chain complex was found to enter the cells more slowly than the immunotoxin alone (Figure 7a ). Once inside the cell both types of complex were found in acidic compartments but the levels found at 10-60 min after internalisation were greater for the immunotoxin alone than for the B chain-treated complex (Figure 7b ). There was a significant difference between the amount of labelled Fib75-SS-ricin A and the immunotoxin with B chain found in the lysosomes at times later than 30 min after uptake by the cell (Figure 7c ). Approximately 80% of the cell-associated Fib75-SS-ricin A was found in the lysosomes at 24 h compared with only 15% of the conjugate plus B chain.
Internalisation of the native (unlabelled) ligands
The preceding experiments clearly demonstrated differences in the mode of internalisation and fate of the two conjugates (+ and -B chain). However it could be argued that their fates were influenced by the labelling method employed (gold particles). Therefore in the following experiments we have investigated the mode of internalisation of the unlabelled immunotoxins using peroxidase-labelled antibodies and permeabilised cells. The Fib75-SS-ricin A chain conjugate was seen to enter cells exclusively via uncoated pits and uncoated vesicles similarly to the gold-labelled conjugate. Later it was found in endosomes (Figure 8a) . After 1 h of internalisation A chain was detected in Golgi-associated vesicles but none was detected in parallel membranes of the Golgi cisternae ( Figure  8b ). At later timepoints most of the immunotoxin was found in secondary lysosomes (Figure 8c ). Fib75-SS-ricin A complexed with ricin B chain bound to the plasma membrane at 4°C in a manner similar to Fib75-SS-ricin A alone, but after warming to 37°C was seen to localise spontaneously in coated pits, enter the cells predominantly in coated vesicles and gain access to the endosomal system (Figure 9a ). At timepoints later than 30 min, label was found in multivesicular endosomes (Figure 9c ) and in the parallel membranes of the Golgi complex (Figure 9b) . At later timepoints, label was found on extracellular vesicles associated with the plasma membrane in a manner identical to that seen with the gold-labelled Fib75-SSricin A + ricin B chain complex. Very little immunotoxin with B chain was found in the secondary lysosomes when the native ligands were stained with peroxidase. Figure 10 (panel b) . No labelling was observed when the anti-rabbit-goat IgG-peroxidase conjugate was substituted for the swine-anti-rabbit peroxidase conjugate or when the MB49 mouse cell line was given identical treatments in place of the EJ cell line. Table I shows the toxicity of I h exposures of the EJ cells to the ricin A chain conjugate with and without ricin B chain (in the presence of 100 mM lactose) as a second stage reagent. It can be seen that the ricin B chain treatment in conjunction with Fib75-SS-ricin A increased the toxicity of the conjugate by two orders of magnitude, resulting in a toxic effect similar to that of ricin holotoxin. A I h treatment of the cells with ricin B chain alone did not elicit an inhibitory response. 
Cytotoxicity studies

Discussion
The present study has demonstrated that the moderate cytotoxic effects of Fib75-SS-ricin A can be enhanced significantly by a post-immunolocalisation treatment with ricin B chain. In addition, the rate of protein synthesis inhibition is markedly increased in the presence of the B chain. These considerations led us to speculate on the mode of internalisation of the Fib75-SS-ricin A conjugate in the absence and presence of ricin B chain and to determine whether there might be a correlation between the pattern of internalisation and the levels of toxicity seen in the target cells. It seems likely that the endocytic route taken by the conjugate might play an important role in determining the intracellular organelle from which ricin A chain enters the cytoplasm and hence the kinetics of protein synthesis inhibition and the level of the resultant toxicity.
The present study of the internalisation of the native and gold-labelled conjugates following binding to the target cells at 4°C revealed that the intracellular trafficking of the two types was very similar. Both the native and gold-labelled conjugate bound to the plasma membrane and entered the cells predominantly by the uncoated vesicle pathway and were seen in the endosomal compartments, in multivesicular endosomes and at later times in secondary lysosomes. During the internalisation and routing of the conjugate both major components of the complex, epitopes of the monoclonal antibody and the ricin A chain, were found together in almost all intracellular compartments involved. A low level of segregation of the two target ligands was observed in some early endocytic compartments close to the plasma membrane.
Only the native A chain of Fib75-SS-ricin A was seen to reach the Golgi-associated vesicles but not the Golgi cisternae. This may be due to the increased size of the immunotoxin-gold complex compared with the molecular size of the native immunotoxin. The presence of both sizes of gold particles in the majority of intracellular organelles indicates the stability of the conjugates disulphide linkage even in acidic compartments. Separate administration of Fib75 antibody and ricin B chain to the cells also resulted in the eventual passage of these ligands to the lysosomes. The routing of a monoclonal antibody and a ricin A chain immunotoxin to the lysosomes has also been reported by Calafat et al. (1988) who also observed that the immunotoxin remained intact until it reached the lysosomal compartment. In the present study although no apparent recycling of the conjugate to the cell surface was seen to occur in cells treated with Fib75-SS-ricin A, Fib75 antibody or ricin B chain alone, cells treated with immunotoxin plus B chain generated labelled vesicles at the cell surface (using both the gold and peroxidase labels) that seemed to derive from multivesicular endosomes. In a previous study of the intracellular trafficking of ricin holotoxin (McIntosh et al., 1990) we have observed and measured ricin being returned to the cell surface associated with vesicles being released to the extracellular space from multivesicular endosomes. Subsequently this material was shown to be toxic in cytotoxicity assays (McIntosh, unpublished data) . Exocytosis of vesicles from multivesicular endosomes during the cellular cycling of ligands is similar to that described for the release of the transferrin receptor by reticulocytes (Pau et al., 1985) .
The other major difference observed between the intracel- The route and rate of internalisation of an immunotoxin will be largely determined by the nature of the antigen to which it binds. However, when the Fib75-SS-ricin A chain conjugate is complexed with B chain (Fib75-SS-ricin A-B), the cell surface galactose-containing receptor might be the preferred vehicle for internalisation of the conjugate, particularly if the binding affinity of the monoclonal antibody for the target antigen is low. When lactose is removed from the culture system, the B chain although in association with the 1U A chain of the immunotoxin may be able to bind to galactose-containing receptors on the cell surface and thereby mediate the entry of the immunotoxin to the cell via the coated pit/coated vesicle pathway.
To summarise, the major differences observed in this study between the behaviour of the immunotoxin with and without ricin B chain were that in the presence of B chain: (i) ricin chains appeared in the entire Golgi complex and were not restricted to Golgi-associated vesicles; (ii) the stability of the conjugate in multivesicular endosomes was increased; and (iii) the complex reappeared at the plasma membrane on vesicles that seemed to be produced from the multivesicular endosomes of A chain intoxicated cells. It appears that the conjugate associated with ricin B chain gains access to the cell, is routed intracellularly and recycled to the plasma membrane in a similar manner as described for native ricin holotoxin (McIntosh et al., 1990; . The differences in the patterns of cellular trafficking of immunotoxin containing ricin A chain, with and without associated ricin B chain may well account for the very marked differences in cytotoxic effects observed.
